(R) -AR-13503

• Description:

  (R) -AR-13503 ((R) -AR-13324 M1 metabolite) is the the (R) -enantiomer of AR-13503 (HY-12798C) . AR-13503 is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research[1][2][3].

• Product Name Alternative:

  (R) -AR-13324 M1 metabolite

• UNSPSC:

  12352005

• Target:

  Drug Metabolite; PKC; ROCK

• Related Pathways:

  Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Purity:

  98.20

• Smiles:

  OCC1=CC=C([C@H](CN)C(NC2=CC(C=CN=C3)=C3C=C2)=O)C=C1

• Molecular Formula:

  C19H19N3O2

• Molecular Weight:

  321.37

• References & Citations:

  [1]Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 205-205.|[2]Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 200-200.|[3]Halasz E, et al. AR-13503, a ROCK inhibitor, reduces rod axon retraction during retinal detachment[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 4221-4221.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2377238-62-3]